160 related articles for article (PubMed ID: 15104336)
21. L-2-oxothiazolidine-4-carboxylic acid reduces in vitro cytotoxicity of glucose degradation products.
Breborowicz A; Witowski J; Polubinska A; Pyda M; Oreopoulos D
Nephrol Dial Transplant; 2004 Dec; 19(12):3005-11. PubMed ID: 15507476
[TBL] [Abstract][Full Text] [Related]
22. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
23. Does the biocompatibility of the peritoneal dialysis solution matter in assessment of peritoneal function?
Parikova A; Struijk DG; Zweers MM; Langedijk M; Schouten N; van den Berg N; Duis S; Krediet RT
Perit Dial Int; 2007; 27(6):691-6. PubMed ID: 17984433
[TBL] [Abstract][Full Text] [Related]
24. Glucose degradation products in peritoneal dialysis fluids: do they harm?
Witowski J; Jörres A; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Bender TO; Passlick-Deetjen J; Breborowicz A
Kidney Int Suppl; 2003 May; (84):S148-51. PubMed ID: 12694333
[TBL] [Abstract][Full Text] [Related]
25. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis.
Schaefer B; Bartosova M; Macher-Goeppinger S; Sallay P; Vörös P; Ranchin B; Vondrak K; Ariceta G; Zaloszyc A; Bayazit AK; Querfeld U; Cerkauskiene R; Testa S; Taylan C; VandeWalle J; Yap Y; Krmar RT; Büscher R; Mühlig AK; Drozdz D; Caliskan S; Lasitschka F; Fathallah-Shaykh S; Verrina E; Klaus G; Arbeiter K; Bhayadia R; Melk A; Romero P; Warady BA; Schaefer F; Ujszaszi A; Schmitt CP
Kidney Int; 2018 Aug; 94(2):419-429. PubMed ID: 29776755
[TBL] [Abstract][Full Text] [Related]
26. Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine.
Lee EA; Oh JH; Lee HA; Kim SI; Park EW; Park KB; Park MS
Perit Dial Int; 2001; 21(3):245-53. PubMed ID: 11475339
[TBL] [Abstract][Full Text] [Related]
27. Effects of icodextrin peritoneal dialysis solution on the peritoneal membrane in the STZ-induced diabetic rat model with partial nephrectomy.
Nakao A; Nakao K; Takatori Y; Kojo S; Inoue J; Akagi S; Sugiyama H; Wada J; Makino H
Nephrol Dial Transplant; 2010 May; 25(5):1479-88. PubMed ID: 19759273
[TBL] [Abstract][Full Text] [Related]
28. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.
Schwenger V; Morath C; Salava A; Amann K; Seregin Y; Deppisch R; Ritz E; Bierhaus A; Nawroth PP; Zeier M
J Am Soc Nephrol; 2006 Jan; 17(1):199-207. PubMed ID: 16319192
[TBL] [Abstract][Full Text] [Related]
29. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
30. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model.
Mortier S; Faict D; Lameire NH; De Vriese AS
Kidney Int; 2005 Apr; 67(4):1559-65. PubMed ID: 15780112
[TBL] [Abstract][Full Text] [Related]
31. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
32. Do low GDP neutral pH solutions prevent or retard peritoneal membrane alterations in long-term peritoneal dialysis?
Parikova A; Michalickova K; van Diepen AT; Voska L; Viklicky O; Krediet RT
Perit Dial Int; 2022 May; 42(3):236-245. PubMed ID: 34259088
[TBL] [Abstract][Full Text] [Related]
33. Multidirectional approach to study peritoneal dialysis fluid biocompatibility in a chronic peritoneal dialysis model in the rat.
Wieczorowska-Tobis K; Polubinska A; Wisniewska J; Pawlaczyk K; Kuzlan-Pawlaczyk M; Filas V; Breborowicz A; Oreopoulos DG
Nephrol Dial Transplant; 2001 Mar; 16(3):655-6. PubMed ID: 11239060
[TBL] [Abstract][Full Text] [Related]
34. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation.
Park MS; Kim JK; Holmes C; Weiss MF
Perit Dial Int; 2000; 20 Suppl 5():S33-8. PubMed ID: 11229610
[TBL] [Abstract][Full Text] [Related]
35. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats.
Musi B; Carlsson O; Rippe A; Wieslander A; Rippe B
Perit Dial Int; 1998; 18(3):303-10. PubMed ID: 9663895
[TBL] [Abstract][Full Text] [Related]
36. L-2-oxothiazolidine-4-carboxylate: an agent that modulates lipopolysaccharide-induced peritonitis in rats.
Korybalska K; Wieczorowska-Tobis K; Polubinska A; Wisniewska J; Moberly J; Martis L; Breborowicz A; Oreopoulos DG
Perit Dial Int; 2002; 22(3):293-300. PubMed ID: 12227385
[TBL] [Abstract][Full Text] [Related]
37. Improvement of peritoneal ultrafiltration with peritoneal dialysis solution buffered with bicarbonate/lactate mixture.
Simonsen O; Sterner G; Carlsson O; Wieslander A; Rippe B
Perit Dial Int; 2006; 26(3):353-9. PubMed ID: 16722029
[TBL] [Abstract][Full Text] [Related]
38. Very high daily intraperitoneal doses of carbonyl compounds affect the morphology, but not the exchange characteristics, of rat peritoneum.
Musi B; Braide M; Wieslander A; Rippe A; Albrektsson A; Henle T; Rippe B
Blood Purif; 2001; 19(3):286-92. PubMed ID: 11244188
[TBL] [Abstract][Full Text] [Related]
39. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
Lai KN; Lam MF; Leung JC; Chan LY; Lam CW; Chan IH; Chan HW; Li CS; Wong SS; Ho YW; Cheuk A; Tong MK; Tang SC
Perit Dial Int; 2012; 32(3):280-91. PubMed ID: 22045098
[TBL] [Abstract][Full Text] [Related]
40. Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis.
Sugiyama N; Tawada M; Sun T; Suzuki Y; Kinashi H; Yamaguchi M; Katsuno T; Aten J; Vlahu CA; van Kuppevelt TH; Takei Y; Ishimoto T; Maruyama S; Mizuno M; Ito Y
Clin Exp Nephrol; 2021 Sep; 25(9):1035-1046. PubMed ID: 33999275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
